CN117203236A - 包含4-1bb和ox40结合蛋白的组合物及其使用方法 - Google Patents

包含4-1bb和ox40结合蛋白的组合物及其使用方法 Download PDF

Info

Publication number
CN117203236A
CN117203236A CN202280028792.6A CN202280028792A CN117203236A CN 117203236 A CN117203236 A CN 117203236A CN 202280028792 A CN202280028792 A CN 202280028792A CN 117203236 A CN117203236 A CN 117203236A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
pharmaceutical composition
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280028792.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·宾纽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptevo Research and Development LLC
Original Assignee
Aptevo Research and Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptevo Research and Development LLC filed Critical Aptevo Research and Development LLC
Publication of CN117203236A publication Critical patent/CN117203236A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280028792.6A 2021-02-17 2022-02-17 包含4-1bb和ox40结合蛋白的组合物及其使用方法 Pending CN117203236A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150475P 2021-02-17 2021-02-17
US63/150,475 2021-02-17
PCT/US2022/016776 WO2022178114A1 (en) 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Publications (1)

Publication Number Publication Date
CN117203236A true CN117203236A (zh) 2023-12-08

Family

ID=80738990

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280028792.6A Pending CN117203236A (zh) 2021-02-17 2022-02-17 包含4-1bb和ox40结合蛋白的组合物及其使用方法

Country Status (8)

Country Link
US (1) US20240150483A1 (enExample)
EP (1) EP4294843A1 (enExample)
JP (1) JP2024508746A (enExample)
KR (1) KR20230167025A (enExample)
CN (1) CN117203236A (enExample)
AU (1) AU2022223692A1 (enExample)
CA (1) CA3208339A1 (enExample)
WO (1) WO2022178114A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
MY197202A (en) * 2017-03-16 2023-05-31 Lg Chemical Ltd A liquid formulation of anti-tnf alpha antibody
ES3044118T3 (en) * 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
BR112021013571A2 (pt) * 2019-01-16 2021-09-21 Compass Therapeutics Llc Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
US20220242962A1 (en) * 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40

Also Published As

Publication number Publication date
JP2024508746A (ja) 2024-02-28
AU2022223692A1 (en) 2023-09-21
KR20230167025A (ko) 2023-12-07
CA3208339A1 (en) 2022-08-25
WO2022178114A1 (en) 2022-08-25
EP4294843A1 (en) 2023-12-27
US20240150483A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
EP4406965A1 (en) Interleukin-2 mutant and fusion protein thereof
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2018503399A (ja) 多特異性免疫調節抗原結合構築物
KR20230009441A (ko) 항-tigit 항체, 이의 제조 방법 및 용도
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
US20220081480A1 (en) Anti-tim-3 antibodies
KR102634374B1 (ko) 항―ｏｘ４０ 항체 및 그의 용도
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
KR20230110303A (ko) 폴레이트 수용체 알파에 결합하는 중쇄 항체
KR20230166120A (ko) 새로운 tnfr2 결합 분자
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
CN117203236A (zh) 包含4-1bb和ox40结合蛋白的组合物及其使用方法
US20250368738A1 (en) Anti-cd28 antibodies
AU2024270136A1 (en) Anti-il1rap antibodies
CN119409832B (zh) 靶向PD-L1和TGF-β的双功能分子
AU2016230182B2 (en) Anti-human membrane-type ADAM28 antibody
US20220242962A1 (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2024229369A9 (en) Antibodies targeting human leukocyte antigen cathepsin g peptide complex
WO2025101811A1 (en) Il-7ra targeting antibodies and uses thereof
CN120958019A (zh) 针对人分化簇3蛋白的抗体及其变体
JP2023551907A (ja) 腫瘍関連抗原及びｃｄ３結合タンパク質、関連する組成物、及び方法
EP4185388A1 (en) A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
HK40059550A (en) Methods of administering anti-tim-3 antibodies
HK40058527A (en) Anti-tim-3 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination